Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada
Canadian Hematology Today · 2023
DOI: 10.58931/cht.2023.2121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Hematology Today, 2023. Verfasst von Christopher Venner und 1 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben.
Abstract (Originalsprache)
Multiple myeloma (MM) is a hematologic malignancy characterized by clonal proliferation of plasma cells in the bone marrow leading to end organ dysfunction including hypercalcemia, anemia, renal dysfunction, and/or bony lytic lesions. The median age of diagnosis is 69 years of age with approximately one-third of newly diagnosed patients presenting over age 75. Therefore, a significant portion of patients presenting with newly diagnosed MM are considered ineligible for transplant due to chronological age, comorbidities or frailty. This category represents a largely heterogeneous group of patients. With options for frontline management rapidly changing, practitioners must consider the optimal treatment modality.
Zitieren
APA
Venner, C., & Varghese, J. (2023). Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada. Canadian Hematology Today. https://doi.org/10.58931/cht.2023.2121
Vancouver
Venner C, Varghese J. Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada. Canadian Hematology Today. 2023. doi:10.58931/cht.2023.2121
BibTeX
@article{Venner2023,
author = {Venner, Christopher and Varghese, Julia},
title = {Frontline management of transplant-ineligible newly diagnosed multiple myeloma (TINDMM) in Canada},
journal = {Canadian Hematology Today},
year = {2023},
doi = {10.58931/cht.2023.2121}
}
EUVIMED